10/30/2019
1
CCS Guideline/Position Statement Workshop
How to Identify and Manage Familial Hypercholesterolemia
in Your Practice
Family Medicine Forum
November 1, 2019
CCS Guideline/Position Statement Workshop
Disclosures
• Liam Brunham• Honoraria: Amgen, Sanofi
• Clinical Trials: Cerenis, The Medicines Company
• Sanja Karalic• Honoraria: none
• Clinical Trials: none
CCS Guideline/Position Statement Workshop
Disclosure of Financial Support
• This program has not received financial support from any organization.
• This program has not received in-kind support from any organization.
• Potential for conflict(s) of interest:• N/A
CCS Guideline/Position Statement Workshop
Audience Participation
Go to: Slido.com
enter event code: Z492
1 2
3 4
10/30/2019
2
CCS Guideline/Position Statement Workshop
Learning Objectives
• To review the clinical features and prevalence of Familial Hypercholesterolemia
• To understand and apply the diagnostic criteria for Familial Hypercholesterolemia
• To recognize the importance of cascade screening in Familial Hypercholesterolemia
• To understand and implement first line treatment for patients with Familial Hypercholesterolemia
CCS Guideline/Position Statement Workshop
CCS Guideline/Position Statement Workshop
Case 1
• 46M found on routine screening to have total cholesterol of 7.2 mmol/L, LDL 5.1 mmol/L, HDL 1.6 mmol/L, TG 1.1 mmol/L
• Cardiac risk factors:• History of elevated lipids, first diagnosed at age 40
• No medications
• No known DM, HTN
• Nonsmoker
• Father died of MI at age 49
CCS Guideline/Position Statement Workshop
History
• Previously healthy
• NKDA
• No tobacco/EtoH/illicit drugs
• Family History of “high cholesterol”
• Father was heavy smoker, had fatal MI at age 49“high
cholesterol”
MI 49
?lipids
age 12 age 15
?lipids
5 6
7 8
10/30/2019
3
CCS Guideline/Position Statement Workshop
Physical Examination
• 130/80, HR 87bpm, RR 14, T36.9, 97%RA
• Cardiovascular: normal S1/S2, no S3/S4, no murmurs, no carotid bruit
• Respiratory: clear, no crackles, no wheezing, no increased WOB
• Abdominal: soft, nontender, no palpable masses
• Extremities: normal
CCS Guideline/Position Statement Workshop
Lab Values
• LDL-C 5.1 mmol/L
• HBA1C 5.5
• TSH normal
• Creatinine normal
• Liver enzymes normal
• CBC normal
CCS Guideline/Position Statement Workshop
Audience Question:
What is the most likely diagnosis in this patient?
Slido.com
Event code: Z492
CCS Guideline/Position Statement Workshop
Familial Hypercholesterolemia
• Genetic condition of impaired LDL clearance typically due to a defective LDL receptor secondary to a mutation in the LDLR gene
• Autosomal dominant inheritance
• Associated with very high risk of ASCVD
• High index of suspicion needed
9 10
11 12
10/30/2019
4
CCS Guideline/Position Statement Workshop
Lifelong elevates of LDL–C contributes to early atherosclerosis and cardiovascular disease
Inherited mutations in LDLR, ApoB, PCSK9, or LDLRAP1
Dysfunctional LDL receptors
Elevated LDL–CElevated LDL–C leads to the formation of atherosclerotic
plaques
Atherosclerotic plaques increase the risk of CVD
1. Nordestgaard BG et al. Eur Heart J. 2013;34:3478-90. 2. Hopkins PN et al. J Clin Lipidol. 2011;5(suppl 3):S9-S17. 3. Fahed AC, Nemer GM. Nutr Metab. 2011;8:23.
CCS Guideline/Position Statement Workshop
Audience Question:
What is the prevalence of FH?
Slido.com
Event code: Z492
CCS Guideline/Position Statement Workshop
FH is a Relatively Common Genetic Disease
• FH is the most common autosomal codominant hereditary disorder in the world
• Recent large meta-analysis estimates global FHprevalence is 1:250 people
30.4 million individuals affected worldwide
143,000 individuals affected in Canada
In some regions of Quebec, the prevalence is as high as 1 in 80
Prevalence of Selected Disorders
Akioyamen LE et al. BMJ Open. 2017 Sep 1;7(9):e016461Paquette M et al. Curr Opin Lipidol. 2018 Apr;29(2):59-64.
Disorder Prevalence
FH 1:250
Type 1 diabetes 1:260
HIV 1:600
Cystic Fibrosis 1:3000
CCS Guideline/Position Statement Workshop
Audience Question:
How would you diagnose FH in this patient?
Slido.com
Event code: Z492
13 14
15 16
10/30/2019
5
CCS Guideline/Position Statement Workshop
Recommendation #1
• We recommend that FH be defined using the DLCNC, Simon Broome Registry or FH Canada definition (Strong Recommendation, High-Quality Evidence).
• Values and preferences. There is no “gold standard” for the diagnosis of FH. Currently available definitions rely on a scoring system to increase diagnostic confidence.
CCS Guideline/Position Statement Workshop
Audience question:
At what level of LDL would you consider a diagnosis of FH?
Slido.com
Event code: Z492
CCS Guideline/Position Statement Workshop
Dutch Lipid Clinic Network CriteriaDutch Lipid Clinic Network (DLCN) Criteria for FH
Stratified by Total Score: Definite FH: > 8, Probable FH: 6-8, Possible FH: 3-5, Unlikely FH: < 3Score
Family History
• First-degree relative with known premature coronary and/or vascular disease, or • First-degree relative with known LDL–C > 95th percentile for age and sex
1
• First-degree relative with physical manifestations of FH, or• Children aged < 18 years with LDL–C levels > 95th percentile for age and sex
2
Clinical History • Premature CAD• Premature cerebral or peripheral vascular disease
21
LDL–C (mmol/L)
• > 8.53 • 6.46 – 8.51 • 4.91 – 6.44• 4.01 – 4.89
8531
Physical Examination
• Tendon xanthomas• Arcus cornealis at age < 45 years
64
DNA Analysis Functional mutation in LDLR, APOB, or PCSK9 8
CCS Guideline/Position Statement Workshop
Canadian Definition of FH
Ruel et al. Can J Cardiol. 2018;34:1210
MajorCriteria
MinorCriteria
FH ScreeningCriteria
*LDL-C ≥ 5.0 mmol/L (≥ 40 yr)• LDL-C ≥ 4.5 mmol/L (18-39 yr)• LDL-C ≥ 4.0 mmol/L (< 18 yr)
+
Yes No
**DNA Mutation or Tendon Xanthomas or LDL-C ≥ 8.5 mmol/L
Definite FH
Yes
1st-degree relative with high LDL-Cor
Proband or 1st-degree relative with ASCVD (< 55 yr men; < 65 yr women)
Probable FH
No
Severe Hypercholesterolemia
17 18
19 20
10/30/2019
6
CCS Guideline/Position Statement Workshop
Xanthelasmas
• Soft yellow thin plaques around the eyelids
CCS Guideline/Position Statement Workshop
Corneal Arcus
• White or grey ring around the cornea
CCS Guideline/Position Statement Workshop
Tendon Xanthomas
• Smooth, firm, mobile, skin-colored nodules within extensor tendons
CCS Guideline/Position Statement Workshop
Secondary causes of hypercholesterolemia
Condition Screening Test
Untreated hypothyroidism TSH
Nephrotic syndrome Albumin, Creatinine
Multiple myeloma SPEP
Biliary liver disease (not NASH) Bilirubin, liver enzymes
21 22
23 24
10/30/2019
7
CCS Guideline/Position Statement Workshop
Audience question:
How likely is it that the patient’s siblings and children also have FH?
Slido.com
Event code: Z492
CCS Guideline/Position Statement Workshop
Cascade Screening Is Recommended After a Diagnosis of FH in Probands
ManWoman Woman with HeFH
Man with HeFH
Probability of Detection
Diagnosed with FH
50% in first-degree
relatives
25% in second-degree
relatives
12.5% in third-degree
relatives
ProbandCascade screening is the process of family tracing for identification
of people at risk of a genetic condition
Guidelines and expert panels recommend testing all first-
degree relatives of patients with diagnosed FH
CCS Guideline/Position Statement Workshop
Recommendation # 2
• We recommend that cascade screening (lipid profile) protocols be implemented at the local, provincial and national level in Canada and offered to first-degree relatives of patients with FH (Strong Recommendation, Moderate-Quality Evidence).
CCS Guideline/Position Statement Workshop
Recommendation #3
• We recommend that genetic testing be offered, when available, to complement a diagnosis of FH and enable cascade screening (Strong Recommendation, High-Quality Evidence). The decision to request genetic screening should be made by the treating physician after discussion with the patient. A down-loadable form is available at www.FHCanada.net.
• Values and preferences. Patient preferences and confidentiality must be considered. Genetic testing is currently not available in most provinces.
25 26
27 28
10/30/2019
8
CCS Guideline/Position Statement Workshop
Which of the following statements regarding the patient’s risk of cardiovascular disease are false?
Audience Question
Slido.com
Event code: Z492
CCS Guideline/Position Statement Workshop
Recommendations regarding risk assessment:
• We recommend that current risk calculators (Framingham Risk Score, Pooled Cohort Equation, SCORE) should not be used to determine cardiovascular risk in patients with FH. (Strong Recommendation, Low-Quality Evidence)
• Such scores will underestimate ASCVD risk in patients with FH.
• We suggest that if available, genetic testing should be used to stratify the ASCVD risk in FH patients. (Weak Recommendation, Moderate-Quality Evidence)
• We suggest that conventional risk factors such as age, sex, HDL-C, hypertension, smoking, Lp(a) and diabetes be ascertained in patients with FH. (Weak Recommendation, Moderate-Quality Evidence)
Recommendations
CCS Guideline/Position Statement Workshop
Adapted from Horton et al. J Lipid Res. 2009;50:S172-S177.
Theoretical relationship between cumulative
cholesterol years and development of severe
atherosclerosis
Age (Years)
10
5
0
Cu
mu
lative
LD
L-C
g/d
L-Y
ea
rs
0 20 40 60 80
HoFH NormalHeFH
Threshold for CVD reached by:
• ~ Age 15 y in HoFH patients
• ~ Age 40 y in HeFH patients
• ~ Age >60 y in healthy individuals
CCS Guideline/Position Statement Workshop
Genetic testing for FH – impact on cardiovascular risk
29 30
31 32
10/30/2019
9
CCS Guideline/Position Statement Workshop
Treatment of FH
Which of the following statements regarding FH treatment are true?
Audience Question
Slido.com
Event code: Z492
CCS Guideline/Position Statement Workshop
Benefit of early statin treatment in FH
CCS Guideline/Position Statement Workshop
Nordestgaard B G et al. Eur Heart J 2013;34:3478-3490
Effect of statin therapy on CHD-free survival in FH(P < 0.001 for difference)
CCS Guideline/Position Statement Workshop
Cardiovascular events occurred in 25% of parents by age 40 and 1% of children.
20 year follow-up of parents with FH who were untreated and children who started statins at age 14.
Early treatment of FH is very effective
Luirink et al. New England Journal of Medicine 2019;381:1547
33 34
35 36
10/30/2019
10
CCS Guideline/Position Statement Workshop
Lifestyle Factors: Canadian Cardiovascular Society Recommendations
“We suggest that patients with FH adopt a healthy lifestyle as recommended by the CCS guidelines2 on the diagnosis and treatment of dyslipidemias”
(Weak Recommendation, Low-Quality Evidence)
1. Brunham L et al. Can J Cardiol. 2018 Dec;34(12):1553-63. 2. Anderson TJ et al. Canadian Journal of Cardiology. 2016; 32: 1263-82.
No Smoking Healthy EatingAppropriate Body Weight
Physical Activity Stress Management
CCS Guideline/Position Statement Workshop
Some suggest a goal of LDL-C < 2.5 mmol/L for primary prevention in adults with FH2
Extrapolating from the general population
Target LDL-C Levels for Adults With FH: Canadian Cardiovascular Society Recommendations:
1. Brunham L et al. Can J Cardiol. 2018 Dec;34(12):1553-63. 2. Nordestgaard BG et al. Eur Heart J. 2013 Dec;34(45):3478-90a.
Primary Prevention
Goal for patients with FH without ASCVD is a 50% reduction from baseline (untreated LDL-C)
and LDL-C < 3.5 mmol/L
“In patients with FH and ASCVD, we suggest that targets should follow the recommendations of the CCS guidelines on the diagnosis and treatment of dyslipidemias
(LDL-C < 2.0 mmol/L and non-HDL-C < 2.6 mmol/L)”
(Weak Recommendation, Moderate-Quality Evidence)
CCS Guideline/Position Statement Workshop
Pharmacotherapy for FH: Canadian Cardiovascular Society Recommendations
Brunham L et al. Can J Cardiol. 2018 Dec;34(12):1553-63.
(Strong Recommendation, Low-Quality Evidence)
“Because the diagnosis of FH using validated clinical criteria and/or genotyping may occur at any age and imparts a high, lifelong risk of ASCVD,
we recommend a personalized treatment plan, taking into account, at a minimum, age, additional cardiovascular risk factors, psychosocial and socioeconomic factors,
and personal as well as family preferences, that should be developed as a shared decision Process”
CCS Guideline/Position Statement Workshop
• 60F• Baseline LDL-C 7.6 mmol/L• Hypertension on perindopril/indapamide• Impaired fasting glucose• Family history: brother had a fatal MI at age 27, other brother had stroke in 50s• Father died in 40s, unknown cause; mother had stroke at 62• Asymptomatic, no personal history of cardiovascular disease
• FH diagnosed at age 57 (never treated previously)• Reluctant to start statin
Case 2
37 38
39 40
10/30/2019
11
CCS Guideline/Position Statement Workshop
What treatment target would you aim for in this patient?
Audience Question
Slido.com
Event code: Z492
CCS Guideline/Position Statement Workshop
Classes of Lipid-Lowering Therapies for the Treatment of FH
HeFH=heterozygous familial hypercholesterolemia; LDL=low-density lipoprotein; LDL–C=low-density lipoprotein–cholesterol; PCSK9=proprotein convertase subtilisin-kexin 9; VLDL=very low-density lipoprotein.
1. Ference BA et al. Eur Heart J. 2017;38:2459-2472. 2. Ito MK et al. J Clin Lipidol. 2011;5(suppl 3):S38-S45. 3. Stadler SL et al. Am J Manag Care. 2017;23(suppl 9):S149-S155.
Adapted from Ference BA et al. Eur Heart J. 2017;38:2459-2472.
Lower plasmaLDL–C
PCSK9inhibitors
LDL clearance
Cholesterol pool
Statins
Conversion of hepatic cholesterol to bile acids by bile acid sequestrants
Intestinal cholesterol
absorptionBile acid sequestrants
Ezetimibe
NiacinVLDL
Upregulation of LDL receptors
Cholesterolsynthesis
CCS Guideline/Position Statement Workshop
Efficacy of Lipid-lowering Therapy for Patients With FH
Ezetimibe and PCSK9 inhibitors are recommended for patients with FH who do not meet their lipid targets on maximally tolerated statin therapy
Agent Reduction in LDL–C Levels
High intensity statin (rosuva 20 or 40mg, atorva40 or 80mg)
40–50%
Ezetimibe 15%–20%
PCSK9 Inhibitors 40%–70%
Bile acid resins 15–20%
Niacin 20%–30%
1. Goldberg AC et al. J Clin Lipidol. 2011;5(suppl 3):S1-S8. 2. Gidding SS et al. Circulation. 2015;132:2167-2192. 3. Fujisue K, Tsujita K. J Cardiol. 2017;70:101-106. 4. Ito MK et al. J Clin Lipidol. 2011;5(suppl 3):S38-S45. 5. Guyton JR, Capuzzi DM. Am J Cardiol. 1998;82:82U-84U. 6. Wolfe ML et al. Am J Cardiol. 2001;87:476-479.
CCS Guideline/Position Statement Workshop
Courtoisie Dr Jean Bergeron
Lipoprotein Apheresis for Patients with Homozygous FH
41 42
43 44
10/30/2019
12
CCS Guideline/Position Statement Workshop
• Consider FH in a patient with LDL>5 mmol/L (and family history)
• Initial treatment is to lower LDL-C by at least 50% using a statin
• Screen family members by testing lipid levels
• Consider referral to a specialist if:
• FH plus ASCVD
• Sub-optimal response to statin
• Statin intolerance
• “Severe” FH (LDL-C >8mmol/L)
Summary of Recommendations
CCS Guideline/Position Statement Workshop
Learning Objectives
• To review the clinical features and prevalence of Familial Hypercholesterolemia
• Lifelong elevation of LDL-C and early CVD; Affects 1 in 250 individuals
• To understand and apply the diagnostic criteria for Familial Hypercholesterolemia
• Consider when LDL-C > 5mmol/L; Canadian definition, Dutch criteria
• To recognize the importance of cascade screening in Familial Hypercholesterolemia
• 50% of first degree relatives affected; screen using lipid levels
• To understand and implement first line treatment for patients with Familial Hypercholesterolemia
• Statin therapy is indicated for all patients with FH; ezetimibe and PCSK9i can be added to reach treatment targets
CCS Guideline/Position Statement Workshop
Thank you!
CCS Guideline/Position Statement Workshop
Please fill out your session evaluation now! Complete a session evaluation one of two ways:
YOUR FEEDBACK IS IMPORTANT TO US!
Session #: F168
Session Name: How to Identify and Manage
Familial Hypercholesterolemia in Your Practice
FMF app
Fmf.cfpc.ca
45 46
47 48